Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Barinthus Biotherapeutics (BRNS) EBIAT (2020 - 2025)

Barinthus Biotherapeutics' EBIAT history spans 6 years, with the latest figure at -$11.1 million for Q4 2025.

  • For Q4 2025, EBIAT rose 46.09% year-over-year to -$11.1 million; the TTM value through Dec 2025 reached -$66.4 million, down 8.69%, while the annual FY2025 figure was -$66.4 million, 8.77% down from the prior year.
  • EBIAT reached -$11.1 million in Q4 2025 per BRNS's latest filing, up from -$14.6 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $15.7 million in Q2 2022 to a low of -$23.8 million in Q2 2023.
  • Average EBIAT over 5 years is -$12.3 million, with a median of -$15.5 million recorded in 2021.
  • Peak YoY movement for EBIAT: tumbled 2984.18% in 2021, then surged 280.4% in 2022.
  • A 5-year view of EBIAT shows it stood at -$15.4 million in 2021, then crashed by 37.78% to -$21.2 million in 2022, then increased by 18.77% to -$17.2 million in 2023, then decreased by 19.49% to -$20.5 million in 2024, then soared by 46.09% to -$11.1 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's EBIAT are -$11.1 million (Q4 2025), -$14.6 million (Q3 2025), and -$21.1 million (Q2 2025).